Most Favored Nation Pricing and Affordability of GLP-1RAs for Obesity Treatment in Medicare | Synapse
May 17, 2026Open Access
Most Favored Nation Pricing and Affordability of GLP-1RAs for Obesity Treatment in Medicare
Key Points
The evaluation aims to analyze the 10-year pricing and affordability of GLP-1RAs for obesity under Medicare.
Economic evaluation over a 10-year period
Focus on glucagon-like peptide-1 receptor agonists
Assess impact on affordability in Medicare
Findings indicate potential barriers to access due to pricing
Affordability issues highlighted for long-term obesity treatment
Economic implications suggest necessary pricing reforms for better access
Abstract
This economic evaluation examines the 10-year US pricing and affordability for glucagon-like peptide-1 receptor agonists (GLP-1RAs) for obesity treatment in Medicare.